Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
Background. Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with ineffective treatment. Mycophenolate mofetil (MMF) is an immunomodulatory agent which inhibits lymphocyte proliferation. Objective. We sought to determine the safety and efficacy profile of MMF i...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2011/849035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565690486226944 |
|---|---|
| author | Argyris Tzouvelekis Evangelos Bouros Anastasia Oikonomou Paschalis Ntolios George Zacharis George Kolios Demosthenes Bouros |
| author_facet | Argyris Tzouvelekis Evangelos Bouros Anastasia Oikonomou Paschalis Ntolios George Zacharis George Kolios Demosthenes Bouros |
| author_sort | Argyris Tzouvelekis |
| collection | DOAJ |
| description | Background. Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with ineffective treatment. Mycophenolate mofetil (MMF) is an immunomodulatory agent which inhibits lymphocyte proliferation. Objective. We sought to determine the safety and efficacy profile of MMF in IPF patients. Methods. We retrospectively identified ten patients, who met the ATS/ERS 2000 criteria for IPF and received MMF 2 gr/day for 12 months. All of them had routine laboratory, pulmonary function and radiological (high resolution computed tomography-HRCT) data available and were enrolled in the study. Forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity of the lung for carbon monoxide (DLCO), 6-minute walking distance (6MWD), HRCT scans and routine laboratory data at treatment onset were compared with respective values 12 months after treatment onset. Results. There were no significant alterations in FVC, TLC, DLCO and 6MWD pre- and 6 and 12 months post-treatment. HRCT evaluation showed deterioration of the total extent of disease (P=0.002) and extent of ground-glass opacity (P=0.02). No cases of clinically significant infection, leucopenia, or elevated liver enzymes were recorded. Conclusions. MMF is a safe therapeutic modality which failed to show a beneficial effect both in functional and radiological parameters in a small cohort of IPF patients. |
| format | Article |
| id | doaj-art-fc08a32d67c3441f961c8f723381e782 |
| institution | Kabale University |
| issn | 2090-1836 2090-1844 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-fc08a32d67c3441f961c8f723381e7822025-02-03T01:06:59ZengWileyPulmonary Medicine2090-18362090-18442011-01-01201110.1155/2011/849035849035Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary FibrosisArgyris Tzouvelekis0Evangelos Bouros1Anastasia Oikonomou2Paschalis Ntolios3George Zacharis4George Kolios5Demosthenes Bouros6Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceLaboratory of Pharmacology, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Radiology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceLaboratory of Pharmacology, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceLaboratory of Pharmacology, Democritus University of Thrace, 68100 Alexandroupolis, GreeceDepartment of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, GreeceBackground. Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with ineffective treatment. Mycophenolate mofetil (MMF) is an immunomodulatory agent which inhibits lymphocyte proliferation. Objective. We sought to determine the safety and efficacy profile of MMF in IPF patients. Methods. We retrospectively identified ten patients, who met the ATS/ERS 2000 criteria for IPF and received MMF 2 gr/day for 12 months. All of them had routine laboratory, pulmonary function and radiological (high resolution computed tomography-HRCT) data available and were enrolled in the study. Forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity of the lung for carbon monoxide (DLCO), 6-minute walking distance (6MWD), HRCT scans and routine laboratory data at treatment onset were compared with respective values 12 months after treatment onset. Results. There were no significant alterations in FVC, TLC, DLCO and 6MWD pre- and 6 and 12 months post-treatment. HRCT evaluation showed deterioration of the total extent of disease (P=0.002) and extent of ground-glass opacity (P=0.02). No cases of clinically significant infection, leucopenia, or elevated liver enzymes were recorded. Conclusions. MMF is a safe therapeutic modality which failed to show a beneficial effect both in functional and radiological parameters in a small cohort of IPF patients.http://dx.doi.org/10.1155/2011/849035 |
| spellingShingle | Argyris Tzouvelekis Evangelos Bouros Anastasia Oikonomou Paschalis Ntolios George Zacharis George Kolios Demosthenes Bouros Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis Pulmonary Medicine |
| title | Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis |
| title_full | Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis |
| title_fullStr | Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis |
| title_full_unstemmed | Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis |
| title_short | Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis |
| title_sort | effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis |
| url | http://dx.doi.org/10.1155/2011/849035 |
| work_keys_str_mv | AT argyristzouvelekis effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT evangelosbouros effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT anastasiaoikonomou effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT paschalisntolios effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT georgezacharis effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT georgekolios effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis AT demosthenesbouros effectandsafetyofmycophenolatemofetilinidiopathicpulmonaryfibrosis |